This is the current revision of this page, as edited by JWBE (talk | contribs) at 18:08, 21 October 2024 (removed Category:Phenols; added Category:4-Hydroxyphenyl compounds using HotCat). The present address (URL) is a permanent link to this version.
Revision as of 18:08, 21 October 2024 by JWBE (talk | contribs) (removed Category:Phenols; added Category:4-Hydroxyphenyl compounds using HotCat)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compoundClinical data | |
---|---|
Trade names | Tandearil, Tanderil |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.489 |
Chemical and physical data | |
Formula | C19H20N2O3 |
Molar mass | 324.380 g·mol |
3D model (JSmol) | |
Chirality | Racemic mixture |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID). It is a metabolite of phenylbutazone.
It was withdrawn from markets worldwide in mid-1980s due to bone marrow suppression and the risk of Stevens–Johnson syndrome.
In Scrabble, the word "oxyphenbutazone" is the present highest scoring word resulting in 1,780 points based on the NASPA word list of 2006.
References
- Singh N, Jabeen T, Somvanshi RK, Sharma S, Dey S, Singh TP (November 2004). "Phospholipase A2 as a target protein for nonsteroidal anti-inflammatory drugs (NSAIDS): crystal structure of the complex formed between phospholipase A2 and oxyphenbutazone at 1.6 A resolution". Biochemistry. 43 (46): 14577–83. doi:10.1021/bi0483561. PMID 15544328.
- Matthews NS, Peck KE, Taylor TS, Mealey KL (May 2001). "Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys". American Journal of Veterinary Research. 62 (5): 673–5. doi:10.2460/ajvr.2001.62.673. PMID 11341383.
- Fung M, Thornton A, Mybeck K, Wu JH, Hornbuckle K, Muniz E (January 2001). "Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999". Therapeutic Innovation & Regulatory Science. 35 (1): 293–317. doi:10.1177/009286150103500134. S2CID 73036562.
- Biron P (May 1986). "Withdrawal of oxyphenbutazone: what about phenylbutazone?". CMAJ. 134 (10): 1119–20. PMC 1491052. PMID 3697857.
- Wood D (22 May 2008). "Record for the Highest Scoring Scrabble Move". Scrabulizer. Archived from the original on 11 May 2023.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA) | |
---|---|
pyrazolones / pyrazolidines | |
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; WHO-Essential Medicines; withdrawn drugs; veterinary use. | |
Topical products for joint and muscular pain (M02) | |||||||
---|---|---|---|---|---|---|---|
Anti-inflammatory preparations, non-steroids |
| ||||||
Capsaicin derivatives | |||||||
Other |
This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |